Dr. Marianna Koczywas
Claim this profileCity of Hope Comprehensive Cancer Center
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
14 reported clinical trials
22 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR positive
2Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Marianna Koczywas is currently running
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting1 award Phase 1 & 27 criteria
More about Marianna Koczywas
Clinical Trial Related6 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Marianna Koczywas has experience with
- Pembrolizumab
- Pemetrexed Disodium
- Carboplatin
- Paclitaxel
- Ramucirumab
- Gemcitabine Hydrochloride
Breakdown of trials Marianna Koczywas has run
Non-Small Cell Lung Cancer
Lung Cancer
Malignant Pleural Mesothelioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marianna Koczywas specialize in?
Marianna Koczywas focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Marianna Koczywas currently recruiting for clinical trials?
Yes, Marianna Koczywas is currently recruiting for 3 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Marianna Koczywas has studied deeply?
Yes, Marianna Koczywas has studied treatments such as Pembrolizumab, Pemetrexed Disodium, Carboplatin.
What is the best way to schedule an appointment with Marianna Koczywas?
Apply for one of the trials that Marianna Koczywas is conducting.
What is the office address of Marianna Koczywas?
The office of Marianna Koczywas is located at: City of Hope Comprehensive Cancer Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.